Join
Live feed
·
PRReleasevia Quantisnow
Cognition Therapeutics Inc. logo

Cognition Therapeutics Announces Positive Topline Results for CT1812 Phase 2 SEQUEL Study for Mild-to-Moderate Alzheimer's Disease

ByQuantisnow·Wall Street's wire, on your screen.
CGTX· Cognition Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track CGTX (Cognition Therapeutics Inc.) and more on Quantisnow.